

BEST AVAILABLE COPY

PCT/EP200 4 / 0 0 8 4 6 4



PCT/EP04/8464



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 30 AUG 2004

WIPO PCT


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Andrew Gray

Dated 23 June 2004



1/77
30 JUL 03 E825257-1 000245
P01 700 0200-0317733.4

Request for grant of a patent


(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

The Patent Office

Cardiff Road
Newport
South Wales NP10 8QQ

1.	Your reference	VA/H-33271P1		
2.	Patent application number (The Patent Office will fill in this part)	29 JUL 2003 0317733.4		
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	NOVARTIS AG LICHTSTRASSE 35 4056 BASEL SWITZERLAND 07185487005 Patent ADP number (if you know it) If the applicant is a corporate body, give the country/state of its incorporation		
4.	Title of invention	Organic compounds		
5.	Name of your agent (If you have one) "Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	Bernard Marsh Novartis Pharmaceuticals UK Limited Patents and Trademarks Wimblehurst Road Horsham, West Sussex RH12 5AB 07181522002		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day/month/year)
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. (see note (d))	Yes		

Patents Form 1/77



9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 20
Claim(s) 3
Abstract 1
Drawing(s) 2 + 2

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) One

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

Bernard Schnerr

29th July 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. S. Schnerr

01403 323069

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay please contact the Patent Office.

Organic Compounds

Field of the Invention

The invention relates to a novel secreted protein from *Photobacterium damsela* subsp. *piscicida*, and to use of the protein or a nucleic acid sequence encoding the protein in a vaccine against pasteurellosis in fish.

Background of the Invention

Mortalities resulting from infections with *Photobacterium damsela* subsp. *piscicida* (formerly *Pasteurella piscicida*) cause the most significant losses in warm water marine aquaculture worldwide. The disease (pasteurellosis) has great economic impact in Japan, where it affects mainly yellowtail cultures, and in the Mediterranean area, due to the losses it causes in sea bream and sea bass farms. Antibiotic therapy is generally ineffective and undesirable due to its negative environmental impact. The development of a vaccine against this disease has been slow, predominantly as a result of the pathogen being facultatively intracellular, and therefore not generally exposed to immune defence mechanisms. Until now, vaccine research has focused on bacterins prepared from heat- or formalin-killed cells. A bacterin vaccine enriched in extracellular products (ECPs) called "DI21" has been commercialized in certain European countries. The degree of efficacy obtained with these bacterins is highly variable and the duration of protection is often short.

There is an unmet need in the field to deliver an inexpensive, easy to manufacture, and reproducibly effective vaccine against *Photobacterium* infection.

Summary of the Invention

In a first aspect, the invention provides an isolated or purified 55kDa extracellular protein from *Photobacterium damsela* subsp. *piscicida*, or a derivative thereof, and antibodies raised thereto.

In a second aspect the invention provides an isolated nucleic acid sequence encoding the 55kDa protein or a homologue or fragment thereof, or a sequence which hybridizes thereto.

under stringent conditions. Also provided are a DNA expression vector carrying the p55 nucleic acid sequence, and a host cell transformed with the DNA expression vector.

In a third aspect, the invention provides a vaccine composition comprising an isolated or purified 55kDa extracellular protein from *Photobacterium damsela* subsp. *piscicida*, or a derivative thereof, and a pharmaceutically acceptable carrier.

In a further aspect, the invention provides the use of an isolated or purified 55kDa extracellular protein from *Photobacterium damsela* subsp. *piscicida*, or a derivative thereof, as a medicament.

In another aspect, the invention provides the use of an isolated or purified 55kDa extracellular protein from *Photobacterium damsela* subsp. *piscicida*, or a derivative thereof, in the manufacture of a medicament for the prevention or treatment of pasteurellosis in fish.

In yet another aspect, the invention provides a method of preventing or treating pasteurellosis in fish, comprising administering to a fish a vaccine composition comprising an isolated or purified 55kDa extracellular protein from *Photobacterium damsela* subsp. *piscicida*, or a derivative thereof, and a pharmaceutically acceptable carrier.

In a further aspect, the invention provides a method of preparing a vaccine against pasteurellosis, comprising the steps:

- (a) growing *Photobacterium damsela* subsp. *piscicida* cells in culture, optionally to mid-exponential phase;
- (b) separating supernatant from the cells;
- (c) optionally, concentrating the supernatant; and
- (d) inactivating the supernatant with an inactivating agent.

The inactivating agent is preferably formaldehyde. Also comprised within the invention is a vaccine composition comprising an inactivated cell culture supernatant from *Ph. damsela* subsp. *piscicida*, wherein said cell culture supernatant is rich in p55.

Description of the Figures

Figure 1 (SEQ ID NO:1) shows the DNA sequence of the p55 protein identified in MT1415 (a virulent strain of *Ph. damsela* subsp. *piscicida*).

Figure 2 (SEQ ID NO:2) shows the deduced amino acid sequence of p55; the 16 amino acid signal sequence which may be cleaved to form the mature protein is shadowed.

Detailed Description of the Invention

The protein which is the subject of the present invention was purified from a preparation of extracellular products (ECP) from virulent *Photobacterium damsela* susp. *piscicida*. By SDS-PAGE this purified protein was judged to run alongside a 55kDa marker. For convenience, this protein shall be referred to as the 55kDa protein or p55. It has been discovered that this protein plays an important role in inducing apoptosis in peritoneal phagocytes during infection. The 55kDa protein has been cloned and sequenced; the DNA sequence and deduced amino acid sequence are depicted in Figures 1 and 2, respectively. The "isolated" p55 gene or nucleic acid sequence is understood to mean the gene or sequence other than in its natural context within the *Ph. damsela* genome.

The 55kDa protein of the present invention is distinct from the so-called 55kDa ECP protein complex from *Photobacterium* disclosed in WO 01/10459, which in fact is nearer to 52kDa in size. That 55kDa ECP complex was shown to consist of at least two different entities, neither of which has an N-terminal sequence related to the p55 sequence disclosed herein. The 55kDa ECP complex of WO 01/10459 is expressed in iron supplemented culture conditions, whereas the 55kDa protein of the present invention is the major secreted protein at mid-exponential phase independent of the level of iron in the culture medium. Furthermore, when antiserum raised against the WO 01/10459 55kDa ECP complex was used to treat ECP preparations to remove this protein, the apoptogenic properties of the treated ECP preparation were unaffected.

We wished to assess whether immunization of fish with purified native p55 might provoke a protective immune response against *Photobacterium* infection. However, the protein was found to be highly toxic to fish when administered in native purified form, leading to rapid

death. Instead, we used a method of passive administration to demonstrate that antibodies raised against this 55kDa protein in rabbits (which specifically bind to the p55 secreted by virulent *Photobacterium* cells *in vivo*) are capable of reducing *Photobacterium*-related mortalities to a significant degree (Example 3).

The benefits of passive immunization can be surpassed by active immunization, whereby antibodies are raised to the 55kDa protein by the fish themselves, following vaccination with a derivative of the protein which is less toxic than the native form, as demonstrated in Example 4.

A "derivative" of the protein refers to a variant of the 55kDa protein which has an altered primary, secondary and/or tertiary amino acid sequence compared to the naturally-occurring (native) protein; it includes the native 55kDa protein which has undergone one or more chemical or physical processing steps resulting in a reduction in toxicity of the protein to fish. The derivative may lack or may include the signal sequence (amino acids 1-16). An "immunogenic" derivative is one capable of eliciting antibodies that neutralize pathogen infectivity and/or mediate antibody-complement or antibody dependent cell cytotoxicity to provide protection against pasteurellosis in an immunized host. The immunogenicity of a derivative can be tested by immunizing an animal and checking to see whether antiserum from the animal is capable of specifically recognizing p55 (e.g. by Western blotting analysis). A detoxified immunogenic derivative of p55, when administered to susceptible fish, results in a positive RPS (relative percent survival) relative to saline-injected control fish when both are challenged with virulent *Ph. damsela*.

For instance, a detoxified immunogenic derivative of the 55kDa protein may be a substantially homologous recombinant variant which has been engineered by site-directed mutagenesis to eliminate or reduce the toxicity of the protein to fish, yet maintain the ability to induce, in fish, the production of antibodies that recognize and (cross)-react with the antigens from *Photobacterium* and/or to induce an immune response in fish that protects against infection with this pathogen.

Alternatively, the derivative may be native p55 or isolated or purified p55 which has been subjected to heat treatment, microwaves, light, water treatment, sonication, cold treatment, freezing, freezing and thawing, lyophilization, denaturation with urea or detergents,

formaldehyde treatment, or any other treatment known to cause alterations in the 3D conformation of proteins.

The derivative of native p55 may be provided in the form a preparation of extracellular products from *Ph. damselae* subsp. *piscicida*. We have discovered that p55 is the major secreted protein in bacterial cultures grown to mid-exponential phase, constituting greater than 85% of the secreted protein under these conditions (older bacterial supernatants – late exponential to stationary phase – have a much more complex protein pattern, although p55 is also present). The invention in one aspect relates in general to inactivated ECP preparations enriched in p55 for use in vaccines. Preferably these ECP preparations are prepared under normal iron conditions, i.e. the cells are grown in culture medium neither supplemented with iron nor incorporating iron chelating agents. The iron concentration of the medium is preferably <15µM, more preferably <10 µM, more preferably <1µM, and most preferably <0.1µM. A preferred embodiment of the invention relates to a vaccine comprising a concentrated culture supernatant from *Ph. damselae* subsp. *piscicida*, preferably grown to mid-exponential phase, which has been inactivated. "Mid-exponential phase" means to an optical density (OD) at 600nm of 0.5-0.7, preferably 0.55-0.65, more preferably about 0.6. The supernatant is preferably separated away from the cells before the inactivation step. The cell culture supernatant is optionally concentrated for use (before or after inactivation), for instance 1.5 – 200 fold, optionally 5-150 fold, for example 50-100 fold. Conventional methods for concentrating the supernatant can be employed, including centrifugal filter devices, ultracentrifugation, vacuum dialysis, ammonium sulphate precipitation, and the like. Example 1 indicates one way of preparing a concentrated culture supernatant, and Example 4 teaches an inactivation step with formaldehyde. Suitable examples of inactivating agents include formaldehyde, saponins, beta-propiolactone (BPL), and binary ethyleneimine (BEI).

In one embodiment the derivative is recombinantly expressed, having an identical amino acid sequence to the native p55 (plus/minus signal sequence), but as a consequence of recombinant expression within a host cell the folding, glycosylation or other post-translational processing of the protein differs from that of the protein in the native state. Any differences in conformation or chemical properties can be reflected in reduced toxicity to fish. For instance, the recombinantly expressed protein from *E. coli* used for immunization in Example 4 forms inclusion bodies, probably due to misfolding.

The derivative may be a non-toxic portion, fragment or epitope of the protein, for instance prepared by cloning and recombinant expression of the protein, or by enzymatic cleavage and/or chemical cleavage of the protein, followed by purification of a protein fragment. In one embodiment the derivative is a fragment of p55, prepared by digestion with a proteolytic enzyme such as trypsin or by cleavage with a chemical such as cyanogen bromide.

For present purposes a "portion" or "fragment" of the p55 protein is understood to mean any peptide molecule having at least 6, preferably at least 10, more preferably at least 15, more preferably at least 25, optionally at least 35, or at least 45 contiguous amino acids of the 55kDa protein. A "portion" of the protein may be the full-length amino acid sequence.

An "isolated" or "purified" protein is defined as being substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of the protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of 55kDa protein having less than about 30% (by dry weight) of non-55kDa protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of contaminating protein, still more preferably less than about 10% of contaminating protein, and most preferably less than about 5% contaminating protein. When the 55kDa protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

There are several different geographical isolates of *Photobacterium damsela* susp. *piscicida*. Examples of strains familiar to researchers in the field include MT1415, PP3, MT1375, MT1588, MT1594, DI 21, B51, EPOY 8803-II, PTAVSA95, ATCC 29690, CECT (Colección Espanola de Cultivos Tipo) 4780, CECT 4781, CECT 5063 and CECT 5064. There is a certain degree of variation in nucleic acid sequence of these strains and in the amino acid sequences of the proteins they express. The 55kDa protein used in the invention is not restricted to any specific strain source but it may be absent from certain non-virulent strains of *Ph. damsela*, such as ATCC 29690 and EPOY 8803-II. A skilled person can

easily test for absence of this protein in a strain by SDS-PAGE analysis or Western blotting analysis, by PCR, or by replicating the apoptosis assay described in do Vale et al. Fish & Shellfish Immunology 15 (2003): 129-144. There may be an advantage in matching the 55kDa variant with the prevalent strain in a particular geographical zone when designing a vaccine for that area.

The invention encompasses derivatives being nucleic acid sequences and amino acid sequences which are substantially homologous to the sequences provided in SEQ ID NO:1 and SEQ ID NO:2, respectively. "Substantially homologous" means that a sequence, when compared to a reference sequence, has at least 50% homology, more preferably at least 60% homology, more preferably at least 70% homology, more preferably at least 80%, 85%, 90%, 95%, 98% or greater homology to the reference sequence.

To determine the percent homology of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g. gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence and the intervening non-homologous sequence in the gap can be disregarded for comparison purposes). There is no requirement for the two sequences to be the same length. Unless otherwise specified, the length of sequence across which the sequences are compared is the entire extent of the alignment. Optionally, the length of a reference sequence aligned for comparison purpose is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least, 70%, 80%, or 90% of the length of the reference sequence.

When a position in the first (reference) sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the sequence, the molecules are homologous at that position (i.e. there is identity at that position). In the case of nucleic acid sequence comparison there is also homology at a certain position where the codon triplet, including the nucleotide encodes the same amino acid in both molecules being compared, due to degeneracy of the genetic code.

The percent homology between two sequences is a function of the number of homologous positions shared by the sequences (i.e., % homology = no. of homologous positions/total no.

of positions). Optionally, the comparison of sequences and determination of percent homology can be accomplished using a mathematical algorithm. Suitable algorithms are incorporated in to the NBLAST and XBLAST programs of Altschul et al. (1990) J. Mol. Biol. 215:430-10.

Also comprised within the nucleic acid sequences of the invention are sequences which hybridize to the reference SEQ ID NO:1 under stringent conditions. "Stringent" hybridization conditions in the sense of the present invention are defined as those described by Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), 1.101-1.104, i.e. a positive hybridization signal is still observed after washing for 1 hour with 1x SSC buffer and 0.1% SDS at 55°C, preferably at 62°C and most preferably at 68°C, in particular for 1 hour in 0.2 x SSC buffer and 0.1% SDS at 55°C, preferably at 62°C and most preferably at 68°C.

The sequences of the invention include fragments of the reference nucleic acid sequence. A "fragment" of the 55kDa protein nucleic acid reference sequence is any part of that sequence comprising at least 10, preferably at least 20, more preferably at least 30, more preferably at least 50, optionally at least 75, or at least 100 consecutive nucleotides. One application of fragments of SEQ ID NO:1 is in the diagnosis of pasteurellosis or infection by virulent *Photobacterium damsela* subsp. *piscicida*. For instance, such fragments may be used as DNA primers in a diagnostic PCR kit.

Another aspect of the invention pertains to vectors, preferably expression vectors, comprising a nucleic acid sequencing encoding p55 (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a plasmid, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are in the form of plasmids. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, operatively linked to the nucleic acid sequence to be expressed. Expression vectors of the invention may be eukaryotic expression vectors used for expression within the intended recipient of the 55kDa antigen (as a DNA vaccine) or prokaryotic or eukaryotic expression vectors for expression within a host organism other than the final recipient (for production of recombinant antigen vaccines). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Within an expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g. 55kDa proteins, derivative forms of p55, fusion proteins of p55 with a heterologous peptide, etc.).

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced by transformation. A host cell can be any prokaryotic or eukaryotic cell (including a eukaryotic cell within a multicellular eukaryotic organism), such as *E. coli*, insect cells (using baculovirus expression vectors), yeast cells or mammalian cells. Other suitable host cells are known to those skilled in the art (e.g. Goeddel, *supra*).

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D. B. and Johnson, K. S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Purified native p55 is also encompassed within the scope of the invention, and it can be extracted or purified from *Ph. damselae* cell cultures using conventional protein purification procedures.

The p55 gene can be incorporated into a Nucleic Acid Vaccine (NAV), whereby the NAV is taken up by host cells of a living animal, and expression of the p55 gene takes place within the cytosol. A p55 gene inserted into a DNA vector can be inoculated directly into a fish (e.g. intramuscularly) for expression in vivo within fish cells. Thus, in one aspect of the invention there is provided a nucleic acid vaccine comprising a pharmaceutically acceptable carrier and a DNA plasmid in which a nucleic acid sequence encoding p55 is operably linked to a transcriptional regulatory sequence. Transcriptional regulatory sequences include promoters, polyadenylation sequences and other nucleotide sequences such as the immune-stimulating oligonucleotides having unmethylated CpG dinucleotides, or nucleotide sequences that code for other antigenic proteins or adjuvanting cytokines. The presence of eukaryotic or viral transcriptional regulatory sequence(s) allows expression of the p55 gene in fish cells. The DNA plasmid itself can be replicated in bacterial cells in order to prepare a vaccine composition, but generally lacks transcriptional regulatory sequences permitting p55 gene expression within prokaryotic cells. For optimal in vivo expression it may be preferred to select transcriptional regulatory sequences endogenous to the fish to be vaccinated. For instance, endogenous cytokine or actin gene promoters may be considered. The DNA can

be present in naked form or it can be administered together with an agent facilitating cellular uptake (e.g. liposomes or cationic lipids). The technology of DNA vaccination of fish is explained in more detail in US 5,780,448, which is incorporated herein by reference.

The vaccine of the invention is intended for administration to any fish at risk from, or suffering from, pasteurellosis. Examples of susceptible species include: yellowtail (*Seriola quinqueradiata*), ayu (*Plecoglossus altivelis*), red seabream (*Acanthopagrus schlegelii*), black sea bream (*Pagrus major*), snake-head fish (*Channa maculata*), red grouper (*Epinephelus akaara*), oval file fish (*Navodon modestus*), striped bass (*Morone saxatilis*), hybrid striped bass (*M. saxatilis* x *M. Chrysops*), gilthead seabream (*Sparus aurata*), sea bass (*Dicentrarchus labrax*), mullet (*Mugil* sp.), yatable blenny (*Pictiblennius yatabei*), Japanese flounder (*Paralichthys olivaceus*) and sole (*Solea senegalensis*).

The typical routes of administration of the vaccine are by injection into the muscle (in particular, apical muscle) or peritoneal cavity (for larger fish), orally in feed, or by immersion in sea water or in fresh water. A preferred vaccination route of an antigenic vaccine is by intraperitoneal injection. It is recommended that fish be at least 2 grams, preferably 10 grams or greater in body weight for administration of the vaccine of the invention by injection. Because certain species of fish are most vulnerable to pasteurellosis when young (such as gilthead sea bream and sea bass), it may be preferred to vaccinate the fish at a weight of 50g or less, optionally by immersion. For immersion or oral administration, a body weight of at least 2 grams is preferred.

The vaccine of the invention may be administered to fish for prophylactic or therapeutic purposes.

The effective dosage of vaccine may vary depending on the size and species of the subject, and according to the mode of administration. The optimal dosage can be determined through trial and error by a veterinarian or aquaculture specialist. Due to the stress suffered by fish in response to vaccination, it is preferred that the vaccine is provided as a single shot vaccine, in single dosage form. Vaccines may suitably comprise between about 1µg and 1000µg, preferably between about 10µg and 200µg, more preferably between about 50µg and 100µg of recombinant or purified protein in a single dosage. Preferably a single dosage

unit is administered to the fish to be treated. For injectable vaccines, a single dosage unit is suitably 0.025 to 0.5 ml, preferably 0.05 to 0.2 ml, optionally about 0.1 ml, in volume.

For DNA vaccines, a minimum dosage of 10pg up to dosages of 1000µg of plasmid per animal should be sufficient for suitable expression of the antigen in vivo.

Typically, vaccines are prepared as liquid solutions, suspensions, or emulsions for injection or for delivery through the ambient water. For instance, a liquid emulsion or emulsifiable concentrate can be prepared in order to be added to a water tank, bath, or sea cage where the fish are held. Solid (e.g. powder) forms suitable for dissolution in, or suspension in, liquid vehicles, or for mixing with solid food, prior to administration may also be prepared. The vaccine may be lyophilized, optionally freeze-dried, in a ready to use form for reconstitution with a sterile diluent or solvent. For instance, lyophilized vaccine may be reconstituted in saline (optionally provided as part of the packaged vaccine product). Nucleic acid vaccines are particularly suited to lyophilisation due to the stability and long shelf-life of the molecules. The pharmaceutical vaccine compositions of the invention may be administered in a form for immediate release or extended release.

In one embodiment of the invention, p55 or a DNA expression vector carrying the p55 coding sequence is combined with a pharmaceutically acceptable carrier or vehicle in a pharmaceutical composition. Pharmaceutically acceptable carriers or vehicles include conventional excipients, and may be, for example, solvents such as water, oil, or saline, dextrose, glycerol, sucrose, tricaine, wetting or emulsifying agents, bulking agents, coatings, binders, fillers, disintegrants, diluents, lubricants, pH buffering agents, or conventional adjuvants such as muramyl dipeptides, avridine, aluminium hydroxide, oils (e.g. mineral oil), saponins, block co-polymers and other substances known in the art. In a preferred embodiment of the invention, a vaccine composition comprises isolated or purified p55 or a derivative thereof, and an adjuvant. The preferred adjuvant is Freund's incomplete adjuvant. Optionally the p55 protein or derivative is suspended in a saline solution (such as PBS) and emulsified with Freund's incomplete adjuvant in a ratio of about 1:1 by volume.

To immunize a fish, a p55 antigen or p55 gene vector can be administered parenterally, usually by intramuscular injection in an appropriate vehicle, injection into the peritoneal cavity, orally in feed, or by immersion. The preferred antigenic vaccine compositions of the

invention are in a form suitable for administration by injection or immersion. DNA vaccination is generally by intra-muscular injection.

The novel antigens disclosed as part of the present invention are also useful in screening for antibodies to *Ph. damselae*, for instance in the preparation of a diagnostic kit for testing fish for exposure to this bacterium.

Antibodies raised against the purified p55 antigen are also comprised within the invention. It is contemplated that such antibodies could have both diagnostic and therapeutic applications in disease management and fish health. Both polyclonal antibodies and monoclonal antibodies may be useful in this respect. Procedures for immunizing animals, e.g. mice, with proteins and selection of hybridomas producing immunogen-specific monoclonal antibodies are well known in the art (see for example Kohler and Milstein (1975) *Nature* 256: 495-497). Sandwich assays and ELISA may be mentioned as specific examples of diagnostic assays.

Examples

Example 1: Cloning and sequencing of p55 from *Ph. Damselae* subsp. *piscicida*

Ph. damselae bacteria (strain MT1415) are grown in tryptic soy broth (TSB) supplemented with NaCl to a final concentration of 1% (w/v) (TSB-1) at 22°C with shaking (100 rpm) to an optical density at 600nm of approximately 0.6 (mid-exponential phase). Bacterial cells are removed by centrifugation and subsequent filtration through a 0.22µm pore size filter. Cell-free supernatants are concentrated 100-fold using a Vivaflow 200 concentrator (Sartorius AG, Goettingen), and dialysed against 20mM Tris-HCl (pH 8.0).

Concentrated culture supernatants are subjected to SDS-PAGE. The 55kDa band is excised from the gel after Coomassie-blue staining. In situ tryptic digestion of the purified protein and Edman degradation of two HPLC-purified peptides is performed.

The fragments yield the following sequences: NNDKPDASDDKYADYVVR and YTAAATEYTVIDALFHSPTFR. The underlined regions are used to design degenerate primers A1 and B, respectively. Total bacterial DNA is prepared from strain MT1415 according to conventional techniques and is used as template for PCR amplifications using

primer A1 and B. The 200bp amplified fragment is excised from an agarose gel, purified using the QIAquick Gel Extraction kit (Qiagen), cloned into the pGEM-T Easy Vector (Promega) following the manufacturer's instructions and sequenced to confirm it corresponds to the desired fragment.

The PCR-derived 200bp fragment described above is labeled with AlkPhos Direct (Amersham Biosciences) and used as a probe for Southern blot analysis of restriction-enzyme digested total DNA from strain MT1415. DNA from agarose slices containing the relevant reactive fragments is extracted using the QIAquick Gel extraction kit (Qiagen). A 3100bp HindIII-HindIII fragment is inserted into pBluescript II KS (Stratagene); a 4100bp NcoI-BamHI fragment is cloned in pET-32b (Novagen). Transformants are selected by PCR using primers A1 and B, and sequenced.

Another DNA probe is generated by PCR using the recombinant plasmid containing the 4000bp NcoI-BamHI fragment and primers P4 (5'-GGCCATGATGAATCTGAAGG-3') and T7 (5'-GTAATACGACTCACTATAGGGC-3'). This DNA fragment is used as a probe on Southern blotting analysis of MT1415 total DNA, following the procedures described above. The region of an agarose gel containing a 1000bp HindIII-HindIII reactive fragment is excised, the DNA is extracted using the QIAquick Gel Extraction Kit (Qiagen) and cloned into the pBluescript II KS vector (Stratagene). Transformants with the desired construct are identified by PCR using the primers P4 and T7 and sequenced.

The complete DNA sequence of p55 is shown in Figure 1 (SEQ ID NO:1), and the deduced primary structure is shown in Figure 2 (SEQ ID NO:2). The protein is 513 amino acids long, and displays a hydrophobic profile typical of a non-membrane protein. Analysis of the amino acid sequence using SignalP, version 1.1 (www.cbs.dtu.dk/services/signalP) reveals the existence of a putative signal peptide with a cleavage site between amino acid residues 16 and 17. Fortuitously, one of the sequences obtained by Edman degradation of tryptic peptides from p55 starts at amino acid residue 17, an asparagine. Considering that trypsin does not cleave peptide bonds on the carboxyl side of alanine (residue 16), it can be concluded that asparagine 17 represents the N-terminus of the mature protein. The predicted molecular mass of the mature form of the protein (56.185 kDa) is in agreement with the size estimated by SDS-PAGE. Database searches using the primary structure of

p55 reveal some homology between the first 340 amino acid residues of p55 and a putative prophagic protein of unknown function from *E. coli* O157:H7.

Example 2: Expression of p55 in *E. coli*

PCR fragments containing the full length p55 gene are cloned into two different expression vectors: pET-28a(+) (Novagen) and pQE-31 (Qiagen), yielding the recombinant plasmids pETp55 and pQEp55, respectively. *E. coli* cells are transformed by conventional methods and transformants are grown at 37°C with shaking for 8 hours in Luria Broth (LB) supplemented with 50µg/ml kanamycin or with 50µg/ml kanamycin plus 200µg/ml ampicillin for the BL21 *E. coli* strain (pET-28 (+) vectors) and M15 *E. coli* strain (pQE-31 vectors), respectively. These cultures are diluted 1:100 in fresh LB with the respective antibiotics and grown for 3 hours at 37°C with shaking. IPTG is then added to a final concentration of 1mM and growth continues for 5 hours at 37°C. IPTG-induced cells are pelleted by centrifugation.

SDS-PAGE analysis of *E. coli* cells carrying the pETp55 plasmid reveals a robust expression of a non-soluble (present in the inclusion bodies fraction) 57kDa protein. Western blotting analysis of these cells using the antibody directed to p55 (described in Example 3) confirms the identity of this protein. The apparent molecular mass of this protein is 2kDa higher than the one displayed by authentic p55, indicating that the signal sequence of the precursor form of p55 is not cleaved in these *E. coli* cells. The insoluble 57kDa protein does not possess apoptogenic activity.

Western blotting analysis of *E. coli* M15 cells harbouring the pQEp55 expression vector using the antibody against p55 (described in Example 3) reveals a low level of p55 expression. Nevertheless, p55 produced by these recombinant cells displays the correct molecular weight by SDS-PAGE. Furthermore, the expressed protein is found in the soluble fraction obtained after centrifugation of sonicated cells, suggesting that p55 produced in these cells is correctly folded. When these soluble extracts are injected into sea bass, high numbers of apoptotic cells can be observed in the peritoneal cavities 6 hours after injection. The apoptotic effects of the recombinant protein are morphologically indistinguishable from those seen upon injection with purified native p55. Purified native p55 is prepared by diluting concentrated culture supernatants of *Ph. damselae* 1:1 in 2x native-PAGE buffer (the same composition as SDS-PAGE sample buffer, except that no SDS is included and the

concentration of beta-mercaptoethanol is reduced to 5mM) and subsequent separation by 10% Native-PAGE. The lanes on the extremities of the gel are cut, stained with Coomassie blue and used to locate the position of the main protein bands. The slice containing the p55 protein is cut out and minced for extraction by diffusion (at 4°C with gentle agitation) using 20mM Tris-HCl (pH 8.0) as elution buffer,

Example 3: Passive immunization using rabbit antiserum to *Photobacterium* 55kDa protein (Three independent experiments are carried out)

Fish: European sea bass (*Dicentrarchus labrax*) having a body weight of about 100g are held in glass aquaria with UV sterilized sea water supplied through a biofilter in a recirculating system. The water temperature is a constant $23 \pm 1^\circ\text{C}$ and salinity is 35‰.

Production of immune serum: Hyperimmune serum against the 55kDa protein is raised in rabbits using 3 doses of the purified protein emulsified in Freund's incomplete adjuvant. The purified p55 protein is prepared as follow. Concentrated culture supernatants from strain MT1415 prepared as described in Example 1 above are subjected to Coomassie-blue SDS-PAGE. After electrophoretic separation, the 55kDa band is excised from the gel, minced in elution buffer (0.02% SDS, 10mM beta-mercaptoethanol, 34 mg/ml PMSF) and incubated overnight at 4°C with shaking. The acrylamide suspension is then centrifuged at 3000g for 15 min at 4°C. The supernatant is collected and centrifuged again in the same conditions. The supernatant is collected, frozen at -80°C and lyophilized. Then the lyophilized protein is resuspended in 2ml distilled water and the protein is precipitated with acetone (90% v/v) overnight at -20°C . The precipitated protein is recovered by centrifugation at 3000g for 10 min at 4°C, washed with 90% (v/v) acetone, dried overnight at room temperature and resuspended in PBS. Rabbits are bled 1 week following the final immunization. Control serum is pre-immune serum from the same rabbit.

Challenge: The *Ph. damsela* subsp. *piscicida* strain PTAVSA95 is thawed and inoculated in tryptone soy agar containing 1% NaCl (TSA-1). Cultures are grown overnight and then resuspended in tryptone soy broth agar containing 1% NaCl (TSB-1). The bacterial density is measured by spectrophotometry (Beckman DU-65) at 600nm and dilutions are made until the expected number of colony forming units (CFU) predicted by a curve absorbance/CFU determined previously. Real CFU used as a challenge dose are checked by viable counts of

dilutions in TSB-1 spread on TSA-1 plates 48h after inoculation at 24°C. The challenge inoculum is drawn into syringes and each fish inoculated by intraperitoneal (i.p.) injection with 100µl. For the confirmation of the cause of death the pathogen is re-isolated from the head kidney and/or dead fish by culturing onto TSA-1.

Before vaccination and challenge all fish are anaesthetized in 0.003% (v/v) ethylene glycol monophenyl ether.

Experiment 1

One group of 8 fish receives 100µl per fish of 1st bleed rabbit antiserum raised against the 55kDa protein, by intraperitoneal injection. One group of 8 fish receives 300 µl per fish 1st bleed rabbit antiserum in the same manner. A final control group of 8 fish receives 300 µl per fish of normal rabbit serum. No negative control groups are required due to the highly-characteristic mortalities resulting from *Photobacterium* infection. Fish from each test group are held in independent tanks. Immediately following vaccination, while still under anaesthetic, each fish receives a challenge dose of 2.24×10^7 *Photobacterium* colony forming units (CFUs).

Experiment 2

One group of 8 fish receives 300µl per fish of 1st bleed rabbit antiserum raised against the 55kDa protein, by i.p. injection. One group of 8 fish receives 300µl per fish of 2nd bleed rabbit antiserum. A control group of 8 fish receives 300µl per fish of normal rabbit serum. Fish from each test group are held in independent tanks. Immediately following vaccination, while still under anaesthetic, each fish receives a challenge dose of 1.87×10^7 *Photobacterium* colony forming units (CFUs).

Experiment 3

One group of 8 fish receives 300µl per fish of 2nd bleed rabbit antiserum raised against the 55kDa protein, by i.p. injection. A control group of 8 fish receives 300µl per fish of normal rabbit serum. Fish from each test group are held in independent tanks. Immediately following vaccination, while still under anaesthetic, each fish receives a challenge dose of 2.24×10^7 *Photobacterium* colony forming units (CFUs).

The first mortalities occur on day 1 post challenge, whilst the final mortality occurs on day 5. No further mortalities occur for 8 consecutive days, so the trial is terminated 15 days after immunization and challenge.

Results

While this is only a small scale study, the indications are that antibodies against the 55kDa protein from *Ph. damselae* ECP are effective in protection against an experimental challenge (Table 1). The protective effect is pronounced, particularly when it is considered that rabbit immunoglobulins are unable to activate the teleost complement cascade. Furthermore, the fish will mount an immune response against the rabbit immunoglobulins, reducing antibody numbers and consequently reducing their efficacy further. Thus, the level of protection indicated in this study is highly significant and makes the 55kDa protein a key potential target for development of vaccines against this economically important disease.

Table 1

Experiment	Vaccine	cumulative mortality (%)	RPS	RPS calculated relative to:
1	Immune serum 100µl/1st bleed	63	17	control rabbit normal serum
1	Immune serum 300µl/1 st bleed	38	50	control rabbit normal serum
1	Normal serum 300µl	75	-	n/a
2	Immune serum 300µl/1st bleed	25	50	control rabbit normal serum
2	Immune serum 300µl/2nd bleed	0	100	control rabbit normal serum
2	Normal serum 300µl	50	-	n/a
3	Immune serum 300µl/2nd bleed	13	67	control rabbit normal serum
3	Normal serum 300µl	38	-	n/a



Example 4: Vaccination with p55 as inclusion bodies and in formalin inactivated ECPs

Fish: European sea bass (*Dicentrarchus labrax*) juveniles having a body weight of about 25g at time of vaccination are held at $26 \pm 1^\circ\text{C}$ with UV and, when necessary, ozone-sterilised saltwater (30‰) supplied through a biofilter in a recirculating system.

Vaccines: p55 inclusion bodies – BL21 *E. coli* strain transformed with the pETp55 plasmid (see Example 2) are grown overnight with agitation (120 rpm) in Luria Broth (LB) supplemented with 50µg/ml kanamycin. The culture is then diluted 1:100 in fresh LB supplemented with 50µg/ml kanamycin and grown for 2 hours at 37°C with shaking. Cells are induced by adding IPTG to a final concentration of 1mM and growth continued for 3 hours as above. IPTG-induced cells are pelleted by centrifugation (15 min, 5000 rpm), resuspended in 10ml Buffer A (10mM NaPO_4 pH 7.2, 0.2M NaCl, 1mM EDTA, 1:1000 PMSF at 50 mg/ml, 1:10000 beta-mercaptoethanol) and sonicated 3 times for 25 seconds (1 minute interval) in ice. After transferring to Eppendorf tubes (1ml/tube) and centrifuging (15 min, 13000g) the supernatant is discarded and 1ml buffer A added to each tube. The pellet is then resuspended by sonicating in ice 4 times for 10 seconds (1 min interval) and after centrifugation (15 min, 13000g) the supernatant is discarded. The pellet is resuspended by adding 1ml buffer B (= Buffer A + 1% Triton X-100) and sonicating in ice 4 times for 10 seconds (1 minute interval). After centrifuging as above and discarding the supernatant, the pellet is resuspended in 1ml Buffer A by sonicating in ice 4 times 10 seconds (1 minute interval). The inclusion bodies are collected by centrifugation, resuspended as above in PBS (p55 final concentration 1mg/ml) and emulsified 1:1 in Freund's incomplete adjuvant.

p55 enriched ECPs – 55kDa protein enriched (>85%) extracellular products (ECPs) from *Ph. damselae* subsp. *piscicida* at mid exponential growth phase are prepared as described in Example 1. Before the immunization, the ECPs are diluted to 2µg of protein/µl and inactivated by adding 0.5% (v/v) of formaldehyde (37% formalin solution, Sigma) for 24 hours at 4°C . Any remaining formalin is neutralized by adding 0.04% (v/v) of a 2M sodium thiosulphate solution. 55kDa enriched ECPs are then emulsified 1:1 in Freund's incomplete adjuvant.

Vaccination: One group of 54 fish receives 50µl of the inclusion bodies vaccine per fish by i.p. injection. One group of 43 fish receives 50µl of 55kDa enriched ECPs vaccine per fish in the same manner. One control group of 42 fish receives 50µl of PBS emulsified 1:1 in Freund's incomplete adjuvant per fish by i.p. injection, and another control group of 26 fish is not injected. Fish from each test group are held in independent tanks.

Challenge: the same strain and procedure described in Example 3 are used to prepare the challenge inoculum except that the challenge dose is 5.2×10^6 CFUs in 50µl per fish. For confirmation of death the pathogen is re-isolated from the head kidney of moribund and/or dead fish by culturing onto TSA-1.

The first mortalities occur on day 2 post-challenge, whilst the final mortality occurs on day 8. No further mortalities occur for 8 consecutive days, so the trial is terminated 15 days after immunization and challenge.

Results

The results (shown in Table 2) clearly indicate that both the p55 inclusion body vaccine and the inactivated p55 enriched ECP vaccine are effective in protecting fish against experimental infections with *Ph. damselae*. The fact that similar levels of protection were achieved suggests that p55, and not any other contaminant *Ph. damselae* or *E. coli* protein, is the protective antigen.

Table 2

Vaccine	Cumulative mortality (%)	RPS calculated relative to PBS control	RPS calculated relative to non-injected fish
p55 inclusion bodies	24	61	63
p55 enriched ECPs	19	70	72
PBS	62	n/a	5
Non injected	65	-6	n/a



Claims

1. An isolated or purified 55kDa extracellular protein of *Photobacterium damsela* subsp. *piscicida* having apoptogenic properties, or an immunogenic derivative thereof.
2. An isolated amino acid sequence comprising SEQ ID NO:2, or an immunogenic derivative thereof.
3. An isolated nucleic acid sequence comprising SEQ ID NO:1, or a substantially homologous sequence, or a fragment thereof, or a sequence hybridizing thereto under stringent conditions.
4. An isolated nucleic acid sequence according to claim 3 encoding an immunogenic derivative of SEQ ID NO:2.
5. A vaccine comprising an amino acid sequence derivative according to claim 2, and a pharmaceutically acceptable carrier.
6. A vaccine according to claim 5 wherein said derivative is an immunogenic fragment of SEQ ID NO:2.
7. A vaccine according to claim 5 or claim 6 wherein said derivative is a recombinantly expressed protein.
8. Use of an amino acid sequence or derivative according to claim 2 as a medicament.
9. Use of an amino acid sequence derivative according to claim 2 in the manufacture of a medicament to prevent or treat pasteurellosis in fish.
10. Antibodies raised against the isolated amino acid sequence of claim 2.
11. A DNA expression vector comprising the nucleic acid sequence of claim 3 wherein said nucleic acid sequence is operably linked to a transcriptional regulatory sequence.

12. A host cell transformed with the DNA expression vector of claim 11.
13. A vaccine comprising the DNA expression vector of claim 11, and a pharmaceutically acceptable carrier.
14. A method of preventing or treating pasteurellosis in a fish vulnerable to the disease, comprising administering to said fish a vaccine according to claim 5 or claim 13.
15. A method of preparing a vaccine against pasteurellosis, comprising the steps:
 - (a) growing *Photobacterium damsela* subsp. *piscicida* cells in culture;
 - (b) separating supernatant from the cells;
 - (c) optionally, concentrating the supernatant; and
 - (d) inactivating the supernatant with an inactivating agent.
16. A method according to claim 15 wherein in step (a) the cells are grown until mid-exponential phase, at which point step (b) is carried out.
17. A method according to claim 15 or claim 16 wherein said inactivating agent is formaldehyde.
18. A vaccine composition comprising an inactivated cell culture supernatant or extracellular protein preparation rich in p55 from *Ph. damsela* subsp. *piscicida*.
19. A vaccine composition according to claim 18 wherein said inactivated cell culture supernatant or extracellular protein preparation is the sole immunogenic component of the vaccine composition.
20. A vaccine composition according to claim 18 or claim 19 wherein the cells have been cultured without iron supplementation and in the absence of iron chelating agents.
21. A vaccine composition according to claim 20 wherein said cells have been cultured in medium containing less than 15µm iron.

22. A vaccine composition according to any of claims 18 to 21, wherein said cell culture supernatant is prepared from cell cultures grown to mid-exponential phase.

23. A vaccine composition according to claim 18, obtainable by the method of claim 15.

24. Use of an isolated amino acid sequence according to claim 2 or an isolated nucleic acid sequence according to claim 3, or antibodies according to claim 10 in the manufacture of a test for the diagnosis of infection with *Photobacterium damsela* subsp. *piscicida* or of pasteurellosis in fish.

25. A diagnostics test kit comprising an isolated amino acid sequence according to claim 2 or an isolated nucleic acid sequence according to claim 3, or antibodies according to claim 10, affixed to a matrix.

Abstract

A derivative of a 55kDa extracellular protein from *Photobacterium damsela* subsp. *piscicida* is the basis for a vaccine against *Photobacterium* infection, and thereby protects fish from pasteurellosis.




Figure 1 Nucleic acid sequence of p55 (SEQ ID NO:1)


ATGACAGCAATATTTTCTCTAGCCATAAACTCAAATTTTGTGTTAGCGAACAACGATAA
ACCAGATGCAAGCGATGACAAGTACGCAGACTACGTGGTACGTCTAGGTTTCGGAACATC
CACTAAACCATACTCAGATCATTGAACTTTCCTCTGCAGTATCGAGGGCTGTCCTTCTT
AGTTACCCAAATATAATAGACCGATACACCGCTGCAGCAACTGAATATACGGTGATCGA
TGCTTTTATTTTCATTTCGCTACCTTTTCGACATATCGTTTCTTTTGGTCTTCATAATCAGC
AAGAGAACCTTGGTCATATTCGATATACTAATGAATATGAAATTAACAATAATCGCGAA
GATGAGTTCTCCTTAGTGAGCGAGGTAAGCTACGACGATATAAAAAGCTCTAATGCTCA
GCAAGTTCCCCTAGTTGCATTTTATGAAGCGCGAGAGGACCGCGCGACGGGCACGCCTA
TCGTAAATATGGGTGTAGCTCCTAGTCTTTTTTCTGGCAGATATAGTTGGTGGCAAGAA
GCATTAATCCATGAAATTGTTTCATCACGTTACAGGCTCTAGTGATACTCATGAAGAAAA
TAAGCAAGGGCCTACTGAAATTTTAGCTCAAATGGTCGCGGCGGAACCTTCATTGGGCGA
TACCAACCTTTTAAAGGATATTCAGATCCTGCGAGGGTTCGAAGCGATACAAGAGCGCGAT
TTCCACTCCTTGTGAATATGTTCCAGAGACACGGCAGTGAATTAGGCTTTCTGTTTAC
CAGATTAGCTACGATTGCCAAAGGTAAGAAAGCTTCGCCTGACTTCGGCACCCCTGACCT
CTTTTTTGCTCGGAAGGTATTAGCAGTTTTTCTAAATATCCCGATCAGATGATGATTTT
AACGGGGGCGGCGCCTTTTTTCTCCCTAGCGCTAGCGCCGACAGTTCAGTTGAATGCAC
TTTTGATGTACTAAATCGAATCGAGCCTGTTGATGACTCAATTAAATTTGAAGGGGGGA
ATTTGCTAATTAAAAATGACTTCAAAAACCTAAATTTACGTGTTGCACAGCTTAGCTTT
TTGAACGCAAAAAAAGGTAGCGGATTTTACAGAAAAAATTGGGATTCTTGGAATCCTG
GTATCAAGCTTCTTCATGGAAGAATGGGCTCAATTCGGTCTATATGGGTACGGCCATG
ATGAATCTGAAGGAAACCTCATTTATTCTCCATATGGCATAACCTTCAATGATGGTTCA
TTCTCTATTGGCTTTTCATCGAGAAAGCATATTAATGACAACACGAAGGATGACAATTT
CGTGAAGTTAAATAACGCTAATTGGAGTTCGTTCTACTACGCAGGTCAAATGTTTTTTG
ACAAAAACAAAAGACCTGTAGCGCTTGTTATTACGGAGCCTTTAAATGCTGCTTTTGGC
GCAGGATGGTCTTATATTTATAAAGATGGGAAATGGCACTATGAAGCTCAAGACGATTG
GGATCAGCGTCTATTTAAAGATTTCGACCTTGTCGTTGGATCCCCACGCGCCACAATTCA
TTAATTAA



Figure 2: Amino acid sequence of p55 (SEQ ID NO:2)

MTATPSLAINSNEFLANNDKPDASDDKYADYVVRLGSEHPLNHTQIIELSSAVSRAVLLSYPN
IIDRYTAAATEYTVIDALFHSPTFRHIVSFGLHNQQENLGHIRYTNEYEINNNREDEFSLVSE
VSYDDIKSSNAQQVPLVAFYEAREDRATGTPIVNMGVAPSLFSGRYSWWQEALIHEIVHHVTG
SSDTHEENKQGPTEILAQMVAELHWAIPTFKGYS DPARVEAIQERDFHSLNMFQRHGSELG
FLFTRLATIAKGKKASPDFGTLTSFCSEGISSFPKYPDHDDDFNGGGAFFLPSASADSSVECT
FDVLNRIEPVDDSIKFEGGNLLIKNDFKNLNLRVAQLSFLNAKKGSGFYRKNWDSWKSQAS
SWKNGLNSGLYGYGHDESEGNLIYSPYGITFNDGSFSIGFSSRKHINDNTKDDNFVKLNNANW
SSFYYAGQMFFDKNKRPVALVITEPLNAAFAGAWSYIYKD GKWHYEAQDDWDQRLFKDSTLSL
DPHAPQFIN-

PCT/EP2004/008464



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.